AF
CUE icon

Amalgamated Financial’s Cue Biopharma CUE Stock Holding History

Amalgamated Financial’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$25K Buy
+168
New +$35.6K ﹤0.01% 2674

Other funds holding CUE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's CUE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cue Biopharma (CUE) in Q1 2022: 168 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #2674 among its holdings.

100 funds tracked by Wall St. Rank hold CUE as of Q1 2022.

  • Amalgamated Financial held 168 shares of Cue Biopharma worth $25K as of Q1 2022.
  • Cue Biopharma was a new Amalgamated Financial position in Q1 2022.
  • Cue Biopharma made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2674 holding.
  • 100 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.